Targeting NFE2L2/KEAP1 mutations in advanced non-small cell lung cancer with the TORC1/2 inhibitor TAK-228.

Paul K Paik,Pang-Dian Fan,Besnik Qeriqi,Azadeh Namakydoust, Bobby Daly,Linda Ahn,Rachel Kim,Andrew Plodkowski,Ai Ni,Jason Chang, Rachel Fanaroff,Marc Ladanyi,Elisa de Stanchina,Charles M Rudin

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer（2022）

引用 9|浏览46

暂无评分

摘要

TAK-228 has single agent activity in patients with NRF2 activated LUSC. This study reframes oncogenic alterations as biologically relevant based on their downstream effects on metabolism. This trial represents, to our knowledge, the first successful attempt at metabolically targeting NSCLC, and is a promising targeted therapy for patients with LUSC, who are bereft of genotype-directed therapies.

查看译文

关键词

CB-839,KEAP1,NFE2L2,TAK-228,lung cancer,sapanisertib,squamous cell

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要